Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
Combination with tazobactam substantially enhanced the activity of piperacillin against routine isolates of staphylococci, various Enterobacteriaceae, Acinetobacter anitratus, and Bacteroides fragilis. Tazobactam enhanced the activity of piperacillin more than fourfold against Pseudomonas aeruginosa spp. harboring eight of 12 plasmid-mediated beta-lactamases.
Eliopoulos
G M
GM
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.
Klimm
K
K
Ferraro
M J
MJ
Jacoby
G A
GA
Moellering
R C
RC
D000150:Acinetobacter / Q000187:drug effects; D001419:Bacteria / Q000187:drug effects*; D001441:Bacteroides fragilis / Q000187:drug effects; D002438:Cefoperazone / Q000494:pharmacology; D002969:Clavulanic Acids / Q000494:pharmacology; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects; D006801:Humans; D010397:Penicillanic Acid / Q000494:pharmacology*; D010878:Piperacillin / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology; D011815:R Factors; D013211:Staphylococcus aureus / Q000187:drug effects; D013407:Sulbactam / Q000494:pharmacology; D000078142:Tazobactam; D013982:Ticarcillin / Q000494:pharmacology; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism
D002969:Clavulanic Acids; D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D002438:Cefoperazone; C043215:ticarcillin-clavulanic acid; D010397:Penicillanic Acid; D001618:beta-Lactamases; D013982:Ticarcillin; D013407:Sulbactam; D000078142:Tazobactam; D010878:Piperacillin